Neurocrine’s Ingrezza Adds Huntington’s Indication, May Have Competitive Edge

Neurocrine Biosciences, Inc.’s Ingrezza (valbenazine) won its second indication in the US with approval to treat chorea associated with Huntington’s disease (HD), six years after its Food and Drug Administration approval for tardive dyskinesia. Rival VMAT2 inhibitor Austedo (deutetrabenazine) from Teva Pharmaceutical Industries Ltd. has been approved for both indications since 2017, so Neurocrine’s product is just catching up in the smaller HD chorea market, but it may capitalize on certain competitive advantages.

However, the gap between the two products may be closing in 2023, since Teva won FDA approval in February for Austedo XR, an extended-release version of the original product that...